

CHANGE OF STATUS REPORT
SECTION 11.2 OF NATIONAL INSTRUMENT 51-102

To: British Columbia Securities Commission
Alberta Securities Commission
The Manitoba Securities Commission
Ontario Securities Commission
Autorité des marchés financiers
Financial and Consumer Services Commission (New Brunswick)
Government of Newfoundland and Labrador Financial Services Regulation Division
Nova Scotia Securities Commission
Prince Edward Island Securities Office

Pursuant to Section 11.2 of National Instrument 51-102 – *Continuous Disclosure Obligations*, Mydecine Innovations Group Inc. (the “**Corporation**”) reports that on October 5, 2023, the Corporation’s common shares ceased trading on the NEO Exchange Inc., operating as Cboe Canada. As a result, the Corporation ceased to be a “non-venture issuer”, as that term is defined under National Instrument 51-102.

Dated this 6th day of October, 2023.

MYDECINE INNOVATIONS GROUP INC.

By: /s/ “Josh Bartch”

Name: Josh Bartch

Title: Chief Executive Officer